Real-world Evidence of Implementing eHealth Enables Fluent Symptom-based Follow-up of a Growing Number of Patients with Breast Cancer with the Same Healthcare Resources [0.03%]
实现实世界证据的eHealth使使用相同的医疗资源实现越来越多乳腺癌患者的基于症状的随访成为可能
Maarit Bärlund,Laura Takala,Leena Tianen et al.
Maarit Bärlund et al.
Background: The growing number of new breast cancer (BC) patients has indicated an urgent need for better tools to monitor patients. Due to the increasing number of unscheduled patient calls, two digital applications were...
Post-Diagnosis use of Antioxidant Vitamin Supplements and Breast Cancer Prognosis: A Systematic Review and Meta-Analysis [0.03%]
抗氧化维生素补充剂与乳腺癌预后：系统回顾与元分析
Yong Li,Qimou Lin,Xiaoju Lu et al.
Yong Li et al.
Antioxidant vitamin supplements (AVSs) are widely used among breast cancer survivors. Whether post-diagnosis use of AVSs would impair cancer survival is unclear. To assess the association between breast cancer survival and post-diagnosis AV...
Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies [0.03%]
三阴性乳腺癌的分子分类及靶向疗法的出现
Elizabeth Sakach,Ruth O&#x;Regan,Jane Meisel et al.
Elizabeth Sakach et al.
Triple negative breast cancer (TNBC) represents 15% to 20% of all primary breast cancers and is the most aggressive subtype of breast cancer. There has been rapid progress in targeted therapy and biomarker development to identify the optima...
Competing Nomogram for Late-Period Breast Cancer-Specific Death in Patients with Early-Stage Hormone Receptor-Positive Breast Cancer [0.03%]
早期激素受体阳性乳腺癌患者晚期乳腺癌特异性死亡的竞争提纲法研究
Jingjing Zhu,Hongjuan Zheng,Chenyang Ge et al.
Jingjing Zhu et al.
Background: More than half of early breast cancer recurrences occur after 5 years from the initial diagnosis. An individualized estimate of the risk of late-period breast cancer-specific death (LP-BCSD) after 5 years of e...
Microbiome Assisted Tumor Microenvironment: Emerging Target of Breast Cancer [0.03%]
微生物组辅助的肿瘤微环境：乳腺癌新兴靶点
Rama Rao Malla,Rakshmitha Marni,Seema Kumari et al.
Rama Rao Malla et al.
The microbiome assisted tumor microenvironment (TME) supports the tumors by modulating multiple mechanisms. Recent studies reported that microbiome dysbiosis is the main culprit of immune suppressive phenotypes of TME. Further, it has been ...
William D Sinclair,Xiaoyan Cui
William D Sinclair
Background: CDK4/6 inhibitors have been used to treat hormone receptor-positive HER2-negative advanced breast cancer. Their benefit in HER2-positive breast cancer has not been determined yet. In this study, we investigate...
Circ-RPPH1 knockdown retards breast cancer progression via miR-328-3p-mediated suppression of HMGA2 [0.03%]
环状RNA RPPH1敲低通过miR-328-3p介导的HMGA2抑制来延缓乳腺癌进展
Jing Li,Yinmou Li,Hong Cheng
Jing Li
Background: Circular RNA Ribonuclease P RNA Component H1 (circ-RPPH1) was confirmed to act as an oncogene in many cancers to promote cancer progression. However, the exact function and mechanism of circ-RPPH1 in breast ca...
Fatemeh Toorang,Bahareh Sasanfar,Ahmad Esmaillzadeh et al.
Fatemeh Toorang et al.
Background: The Dietary Approach to Stop Hypertension (DASH) eating pattern has been recommended as a healthy dietary plan by several international guidelines. However, data on the association between the DASH diet and br...
Controversial role of mast cells in breast cancer tumor progression and angiogenesis [0.03%]
肥大细胞在乳腺癌肿瘤进程和血管生成中争议性的作用
Domenico Ribatti,Tiziana Annese,Roberto Tamma
Domenico Ribatti
Breast cancer is a neoplastic disease and is a cause of cancer-related mortality for women. Among cellular and molecular regulators of the microenvironment, mast cells and vascular endothelial growth factor (VEGF), are correlated with tumor...
A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer [0.03%]
第一项人类一期临床试验：新型选择性雄激素受体调节器（SARM），RAD140，在ER+/HER2-转移性乳腺癌中的应用研究
Patricia LoRusso,Erika Hamilton,Cynthia Ma et al.
Patricia LoRusso et al.
Introduction/background: This first-in-human, phase 1 study aimed to characterize the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetic (PK) profile, and antitumor activity of RAD140, an oral selective a...
Clinical Trial
Clinical breast cancer. 2022 Jan;22(1):67-77. DOI:10.1016/j.clbc.2021.08.003 2022